MELBOURNE, Australia, March 23, 2026 /PRNewswire/ — Monash University and ClinChoice Inc, a leading global clinical contract research organization (CRO) focused on innovative therapies, today announced a strategic partnership designed to accelerate early-phase clinical trials and bring breakthrough health innovations and discoveries closer to patients around the world.
Each organization brings distinct strengths to healthcare innovation and both share a clear commitment to improving the health and well-being of patients around the world.
Monash is a Top 50 global universitiesand is Australia’s largest university with a global presence in the Indo-Pacific region, Europe and the United States.
The university is also part of Australia’s largest clinical trials network, spanning five major affiliated health services with more than 7,000 hospital beds and a national network of more than 3,000 GPs. Monash University-led trials account for approximately a quarter of all clinical trial activity in Australia, affecting a patient population of 4.5 million people.
The collaboration combines Monash University’s internationally recognized research excellence and clinical ecosystem with ClinChoice’s global development, regulatory and data science capabilities to support high-quality patient-centered research in Australia and the broader international research landscape. Particular attention will be paid to accelerating early-phase clinical development and making innovative therapies available to patients more quickly.
“Monash is deeply committed to pursuing impact-focused partnerships that leverage our expertise in healthcare research and innovation,” said Professor Robyn Ward AM, Deputy Vice-Chancellor (Research and Enterprise). “We are proud to partner with ClinChoice. By combining our research excellence with their global capacity, we can bring new therapies and technologies to patients while strengthening collaboration between our talented researchers and the global biotechnology sector.
“We are honored to formalize this partnership with Monash University, a globally respected institution at the forefront of pharmaceutical science,” said Kevin Xu, Chief Executive Officer of ClinChoice. “This collaboration is a strong testament to ClinChoice’s mission to support innovation through academic and clinical partnerships.
“By combining our global development experience with Monash’s research excellence, we will advance clinical research in an even more efficient and impactful way, ultimately bringing new treatments to patients more quickly,” added Kerry Dyson, President of International Clinical Operations at ClinChoice.
About Monash University
Monash University is one of Australia’s leading research-intensive universities and a globally recognized leader in the fields of pharmaceutical sciences and pharmacology.
The university ranks among the world’s top 50 universities in the QS World University Rankings 2026, the QS Sustainability Rankings 2026 and the US News and World Report (USNWR) Best Global Universities Rankings 2025-26. Monash has an international reputation for excellence in healthcare research and application, and is ranked third internationally in Pharmacy and Pharmaceutical Sciences and fourth in Pharmacy and Pharmacology.
Through its world-renowned Monash Institute of Pharmaceutical Sciences (MIPS), Monash drives groundbreaking innovations from target identification through to preclinical and translational development. Consistently ranking among the world’s top institutions in pharmacy and pharmacology, Monash plays a central role in advancing new therapies by integrating basic science with strong industrial collaboration to translate research into real-world health outcomes.
The university is home to the Monash Technology Quarterbringing together researchers, industry partners and world-class facilities to drive collaboration and innovation, creating commercial opportunities and delivering significant benefits to communities.
About ClinChoice
ClinicChoice is a global clinical-stage CRO that partners with pharmaceutical and biotechnology companies to translate scientific innovation into clinical impact. With over 30 years of experience and operations in over 15 countries across North America, Europe and Indo/Asia Pacific, ClinChoice brings deep therapeutic expertise in hematology/oncology, immunology and inflammation (I&I), cardiometabolic and CNS. Having completed more than 3,000 studies worldwide, ClinChoice has a strong track record of collaborating with biopharmaceutical companies around the world and implementing early and late phase programs with speed, quality and innovation.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/monash-university-and-clinchoice-forge-strategic-partnership-to-accelerate-clinical-development-of-innovative-therapies-302721802.html
SOURCE ClinChoice Inc.
